Could sotatercept help PAH patients breathe easier?
NCT ID NCT07140484
First seen Nov 01, 2025 · Last updated May 24, 2026 · Updated 41 times
Summary
This study tests whether the drug sotatercept can improve lung function in people with pulmonary arterial hypertension (PAH), a condition that makes it hard to breathe. About 27 adults will receive the drug every 21 days for 29 weeks and undergo lung tests, heart ultrasounds, and blood draws. The goal is to see if the drug helps the lungs take in oxygen better during exercise.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PULMONARY ARTERY HYPERTENSION are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Clinical Physiology Laboratory
RECRUITINGEdmonton, Alberta, T6G2R3, Canada
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.